ライフサイエンスコーパス: femoral neck

1 than women without knee OA (P < 0.04 at the femoral neck).

2 at the lumbar spine (P = 0.038), but not the femoral neck.

3 cartilage of patients with a fracture of the femoral neck.

4 oflavones, except for a modest effect at the femoral neck.

5 to 3.7 percentage points; P < 0.001) at the femoral neck.

6 0.7% (CI, -1.5% to 0.01%; P = 0.081) at the femoral neck.

7 on for impending pathologic fractures of the femoral neck.

8 nd 1.6% (CI, 0.4% to 2.8%; P = 0.008) at the femoral neck.

9 eatment groups had an increase in BMD at the femoral neck.

10 lder age groups, especially at the spine and femoral neck.

11 not a major feature of normal ageing of the femoral neck.

12 lacement for OA or following fracture to the femoral neck.

13 d not experience significant declines at the femoral neck.

14 Bone loss began by the midtwenties at the femoral neck.

15 over the age of 50 have osteoporosis of the femoral neck.

16 cular eccentricity and stresses in the human femoral neck.

17 d with increased bone mineral density of the femoral neck.

18 rence in standardized BMD of the ipsilateral femoral neck.

19 s associated with increased bone loss at the femoral neck.

20 ivity level, and bone mineral density at the femoral neck.

21 esses anterior, posterior, and medial to the femoral neck.

22 core in the lumbosacral spine, total hip, or femoral neck.

23 Similar trends were observed in the hip and femoral neck.

24 S) for impending pathologic fractures of the femoral neck.

25 multiple radial images along the axis of the femoral neck.

26 rochanter (0.026 +/- 0.006 g/cm2, P <0.001), femoral neck (0.022 +/- 0.006 g/cm2, P <0.001), total hi

27 Mean BMD of the femoral neck (0.88 g/cm2; 95% CI, 0.84-0.91 g/cm2 vs 0.9

28 time at multiple anatomical sites, including femoral neck (-0.08%/year per one interquartile increase

29 itamin D and placebo groups were as follows: femoral neck, +0.50+/-4.80 and -0.70+/-5.03 percent, res

30 for age and sex (lumbar spine, +0.7 +/- 1.6; femoral neck, -0.1 +/- 1.1; total hip, 0.0 +/- 1.1).

31 have increased (lumbar spine, -0.2 +/- 1.6; femoral neck, -0.6 +/- 1; total hip, -0.6 +/- 1.1; match

32 (mean Z scores: lumbar spine, -0.4 +/- 1.6; femoral neck, -0.7 +/- 1.1; total hip, -0.7 +/- 1.1).

33 difference, -0.08, 95% CI -0.13 to -0.02 for femoral neck; -0.09, 95% CI -0.15 to -0.03 for lumbar sp

34 placebo at the lumbar spine (5.4% vs 1.1 %), femoral neck (1.6% vs -1.2%), femoral trochanter (3.3% v

35 fidence interval, -2.18 to -1.01; P < 0.001; femoral neck, -1.20%; 95% confidence interval, -1.69 to

36 e loss at either the LS (-8.6+/-1.0%) or the femoral neck (-11.3+/-2.2%).

37 For the femoral neck (18 RCTs, n = 1604), isoflavone treatment s

38 at the spine (3.96%; 95% CI: 4.86%, 3.06%), femoral neck (2.39%; 95% CI: 3.61%, 1.17%), total hip (1

39 the lumbar spine (17 +/- 3%), total hip and femoral neck (24 +/- 3% and 20 +/- 4%, respectively).

40 ad, 8.51-8.73 GPa vs 9.32-9.67 GPa; P = .04; femoral neck, 3.11-3.72 GPa vs 4.39-4.82 GPa; P = .04; W

41 erences: spine, 4.4% [95% CI, 3.3% to 5.5%]; femoral neck, 3.4% [CI, 2.3% to 4.4%]).

42 e estrogen had BMD increases of 2.6% for the femoral neck; 3.6%, total hip; 2.8%, spine; and 1.2%, to

43 o 0.04 (P < 0.00001; 95% CI: 0.02, 0.05) and femoral neck (4 RCTs, n = 524) to 0.03 (P < 0.05; 95% CI

44 erve transection to a level posterior to the femoral neck (8-27 cm) depending on the length of the st

45 al, 8.1 to 12.4 percent), 5.4 percent at the femoral neck (95 percent confidence interval, 3.5 to 7.4

46 sociated with fracture risk independently of femoral neck aBMD and the Fracture Risk Assessment Tool

47 Mean femoral neck aBMD had also increased to a greater extent

48 After further adjustment for femoral neck aBMD or FRAX score, the associations were r

49 load improved prediction of fracture beyond femoral neck aBMD or FRAX scores alone.

50 bular dysplasia, pistol grip deformity, wide femoral neck, altered femoral neck-shaft angle, appear t

51 Femoral neck analysis errors were easily detectable, but

52 There were 24 (0.9%) femoral neck analysis errors, of which 23 resulted from

53 0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites

54 with daily cola intake was 3.7% lower at the femoral neck and 5.4% lower at Ward's area than of those

55 y in the year after critical illness at both femoral neck and anterior-posterior spine sites.

56 X-ray absorptiometry at the lumbar spine and femoral neck and by peripheral quantitative computed tom

57 evere CAL was associated with low BMD of the femoral neck and deleterious clinical dental parameters

58 was no association between bone loss at the femoral neck and fractures regardless of bisphosphonate

59 onide was associated with loss of BMD at the femoral neck and lumbar spine after 3 years of treatment

60 Consistent results were seen for change in femoral neck and lumbar spine BMD and across a range of

61 We measured femoral neck and lumbar spine BMD at baseline and after

62 ifference between participants in BMD at the femoral neck and lumbar spine, respectively.

63 of -0.29 (-0.44 to -0.15, p < 0.001) at the femoral neck and of -0.25(-0.45 to -0.05, p = 0.015) at

64 reases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture.

65 E involves displacement between the proximal femoral neck and the femoral head at the level of the op

66 cant increase of bone mineral density at the femoral neck and the trochanteric region (13% and 15%, r

67 isone therapy, bone mineral densities of the femoral neck and the Ward triangle did not increase sign

68 There was a greater increase in femoral neck and total body BMD and bone mineral content

69 cent change in bone mineral densities at the femoral neck and total hip at 24 months and at all three

70 Loss of BMD at the femoral neck and total hip were also similar between tre

71 ge or older, with normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopen

72 ween-group differences were observed for the femoral neck and trochanter.

73 uted the incidence rates of fractures of the femoral neck and trochanteric region of the proximal fem

74 atients underwent baseline BMD measurements (femoral neck and/or lumbar spine) using dual x-ray absor

75 0(-12) for lumbar spine and p=1.9x10(-4) for femoral neck) and an increased risk of both osteoporotic

76 0(-10) for lumbar spine and p=3.3x10(-8) for femoral neck) and increased risk of osteoporosis (OR 1.2

77 t the lumbar spine, 2.5+/-0.4 percent at the femoral neck, and 2.0+/-0.2 percent for the total body (

78 the lumbar spine, 7.4% at total hip, 7.1% at femoral neck, and 2.3% at one-third radius.

79 the lumbar spine, 9.2% at total hip, 9.0% at femoral neck, and 2.7% at the one-third radius.

80 es in bone mineral density at the total hip, femoral neck, and distal third of the radius at all time

81 lumbar spine vertebrae 2-4, the forearm, the femoral neck, and hip.

82 red with calvaria, maxilla, lumbar vertebra, femoral neck, and iliac crest.

83 reater trochanter, femoral neck, base of the femoral neck, and level of the lesser trochanter.

84 Baseline total hip, femoral neck, and lumbar spine BMDs were 1.016 +/- 0.160

85 ation between stimulant use and total femur, femoral neck, and lumbar spine bone mineral content (BMC

86 (average T scores and Z scores) of the hip, femoral neck, and lumbar spine of IgE-CMA patients were

87 absorptiometric examinations of the forearm, femoral neck, and lumbar spine were performed by 11 tech

88 ctive protein (hsCRP) on BMD at the forearm, femoral neck, and lumbar spine.

89 ensity (BMD) at the lumbar spine, total hip, femoral neck, and one-third radius.

90 nd bone mineral density of the lumbar spine, femoral neck, and proximal radius were measured by dual

91 gy x-ray absorptiometry of the lumbar spine, femoral neck, and radius.

92 also observed at the total hip, total body, femoral neck, and the predominantly cortical one-third r

93 ture had lower aBMD at the spine, total hip, femoral neck, and the ultradistal radius, the last havin

94 ptiometry, was assessed at the lumbar spine, femoral neck, and total femur (grams per square centimet

95 reater decreases in BMD at the lumbar spine, femoral neck, and total hip from the end of year 1 (mean

96 ineral density of the total body, total hip, femoral neck, and trabecular bone of the lumbar spine al

97 l density from baseline at the lumbar spine, femoral neck, and trochanter by 1% to 4% and in the tota

98 included lumbar spine, total proximal femur, femoral neck, and whole-body BMD.

99 pothesis while those in human and chimpanzee femoral necks are not.

100 in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-fo

101 ents at the level of the greater trochanter, femoral neck, base of the femoral neck, and level of the

102 ageing, this thin cortical zone in the upper femoral neck became substantially thinner.

103 sal women have a bone density T score at the femoral neck between -1.0 and -2.5.

104 For bone mineral density T scores at the femoral neck, biomechanical CT analysis was highly corre

105 ; 95% CI, 0.94-0.94 g/cm2; P = .03) and mean femoral neck BMC (4.34 g; 95% CI, 4.13-4.57 g vs 4.59 g;

106 13.38 g; 95% CI, 13.25-13.51 g; P = .03) and femoral neck BMD (0.87 g/cm2; 95% CI, 0.74-0.83 g/cm2 vs

107 intakes were associated with maintenance of femoral neck BMD (FN-BMD) in men (dark fish + tuna, dark

108 the ICS group experienced 6% or more loss of femoral neck BMD (p = 0.002).

109 ink/d of alcohol had a significantly greater femoral neck BMD (P = 0.008) and lumbar spine BMD (P = 0

110 The beneficial effect of current HT use on femoral neck BMD appeared to be greater in women with hi

111 The difference in femoral neck BMD between the same dose quartiles was onl

112 the hypothesis that a major QTL controlling femoral neck BMD is located on chromosome 1p36.2-p36.3,

113 PD patients had lower hip, lumbar spine and femoral neck BMD levels compared with healthy controls;

114 The means +/- SDs of femoral neck BMD loss were -0.02 +/- 0.05 and 0.0 +/- 0.

115 Women aged 54 to 81 years with a femoral neck BMD of 0.68 g/cm2 or less (Hologic Inc, Wal

116 en and 75 black men to predict total hip and femoral neck BMD or changes in BMD.

117 Among older adults with type 2 DM, femoral neck BMD T score and FRAX score were associated

118 d hazard ratios (HRs) for 1-unit decrease in femoral neck BMD T score in women with DM were 1.88 (95%

119 Twins with hip OPH had 3.5% higher femoral neck BMD than their unaffected cotwins.

120 multipoint LOD score of 3.53 for linkage of femoral neck BMD to a quantitative trait locus (QTL) loc

121 for the A593-T598-C620 haplotype (n=85) had femoral neck BMD values 5.7% lower than those who did no

122 Bilateral femoral neck BMD values as well as knee magnetic resonan

123 t of women in the lowest tertile (p = 0.02); femoral neck BMD was 12% greater in the highest versus t

124 Heritability of femoral neck BMD was estimated as 0.51 +/- 0.13 in these

125 Femoral neck BMD was higher in women who had consumed hi

126 , supplement-induced increases in spinal and femoral neck BMD were lost within 2 y of supplement disc

127 The pattern of change in femoral neck BMD with increasing protein intake in the s

128 letal and sexual maturity, anthropometry and femoral neck BMD Z-score to control confounding effects.

129 istic curve was 0.753 for entropy, 0.608 for femoral neck BMD, and 0.698 for NSA.

130 dary endpoints comprised the dose effects on femoral neck BMD, falls, circulating calciotropic hormon

131 s total hip bone mineral density (BMD), with femoral neck BMD, lumbar spine BMD, and lumbar spine tra

132 rCl was associated with greater increases in femoral neck BMD.

133 Similar results were found for femoral neck BMD.

134 one mass, with effects that are specific for femoral neck BMD.

135 se intakes were greater had higher spine and femoral neck BMD.

136 : 1.5%, 5.1%) but no effect on total body or femoral neck BMD.

137 besity was associated with a greater loss of femoral neck BMD.

138 Femoral-neck BMD also increased more in the combination

139 ars to 332,000 dollars, depending on age and femoral neck bone density.

140 to vegetable protein intake have more rapid femoral neck bone loss and a greater risk of hip fractur

141 lumbar spine bone mass and a reduced rate of femoral neck bone loss during lactation.

142 Similarly, changes in spine and femoral neck bone mineral contents (BMCs) were not signi

143 ry, we compared lumbar spine, total hip, and femoral neck bone mineral density (BMD) in 581 HIV-posit

144 he patients had normal lumbar spine (LS) and femoral neck bone mineral density (BMD).

145 strong relation (r = 0.71) between increased femoral neck bone mineral density and increased serum 25

146 Similarly, femoral neck bone mineral density increased more in the

147 , total energy intake, plasma vitamin D, and femoral neck bone mineral density.

148 nd associated with a significant increase in femoral neck bone mineral density; vascular calcificatio

149 The femoral-neck bone density increased by 1.2+/-0.4 percent

150 xifene increased bone mineral density in the femoral neck by 2.1 % (60 mg) and 2.4% (120 mg) and in t

151 various sites, bone density measured at the femoral neck by dual-energy x-ray absorptiometry is the

152 was associated with reduced bone loss in the femoral neck compared with controls (mean +/- SD -0.29+/

153 ws thinning of the underloaded superolateral femoral neck cortex arises from the failure of walking t

154 range of non-destructive metrics to measure femoral neck cortical bone stiffness at the millimetre l

155 ty, as measured by micro-CT, correlated with femoral neck cortical bone's elastic modulus and ultimat

156 After 3 years, BMD at the femoral neck decreased 1.78% more with ICS than with pla

157 lcitriol group), and the mean density at the femoral neck decreased by 6.2 percent (P=0.001 for compa

158 The bone mineral density at the femoral neck decreased by a mean of 1.7 percent in the a

159 Children with systemic JRA had lower femoral neck densities.

160 eight, and cohort, and then additionally for femoral neck DXA aBMD or FRAX.

161 ral density change at both the spine and the femoral neck, even after accounting for prolactin levels

162 including 206 women and men with extreme low femoral neck (FN) BMD.

163 sis at baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, respectively.

164 Lumbar spine (LS), femoral neck (FN), and distal radius (DR) bone mineral d

165 tiles and mean BMD at the lumbar spine (LS), femoral neck (FN), femoral trochanter (FT), and femoral

166 0%; n = 5) but no effect on total hip (TH), femoral neck (FN), or total body BMD or bone biomarkers.

167 mposition and whole-body, lumbar spine (LS), femoral neck (FN), trochanter, and Ward's triangle (WT)

168 for lumbar spine (LS)-, total hip (HIP)- and femoral neck (FN)-bone mineral density (BMD).

169 populations, we built assessment models for femoral neck (FN)-fracture prediction and BMD value pred

170 X-ray absorptiometry at the lumbar spine and femoral neck (FN).

171 d BMD values at the lumbar spine (LS-BMD) or femoral neck (FN-BMD) in probands.

172 bone mineral density at total femur (TFBMD), femoral neck (FNBMD), lumbar spine (LSBMD), and physicia

173 ndom-effects models for the lumbar spine and femoral neck for all studies providing isoflavones as ag

174 .2%, -1.2%) of a z score was observed at the femoral neck for each unit increase in BMD z score at ba

175 s with osteoarthritis (OA) and patients with femoral neck fracture (as normal control).

176 on in hip arthroplasty, especially following femoral neck fracture in the elderly, associated with su

177 50 years of age or older and had a displaced femoral neck fracture to undergo either total hip arthro

178 Eligible patients with femoral neck fracture undergoing hemiarthroplasty were r

179 s and from lesion-free control subjects with femoral neck fracture was assessed by measuring malondia

180 CS for consolidation of impending pathologic femoral neck fracture with a mean follow-up of 533 days

181 ables discrimination of patients at risk for femoral neck fracture, and our results show the potentia

182 isplaced femoral neck fracture, nondisplaced femoral neck fracture, intertrochanteric fracture, previ

183 ng boxes and classified as normal, displaced femoral neck fracture, nondisplaced femoral neck fractur

184 time of joint replacement surgery for OA or femoral neck fracture.

185 s treated with a hemiarthroplasty because of femoral neck fracture.

186 these patients had experienced a low-impact femoral neck fracture.

187 h there was a trend toward a reduced risk of femoral neck fractures in subjects with severe radiograp

188 the hemiarthroplasty treatment of displaced femoral neck fractures in the absence of contraindicatio

189 s of diabetes mellitus, vertebral fractures, femoral neck fractures, and hip fractures were 2-5 times

190 d with cartilage obtained from patients with femoral neck fractures, the expression of both miR-140-5

191 pendently ambulating patients with displaced femoral neck fractures, the incidence of secondary proce

192 For displaced femoral neck fractures, there remains uncertainty regard

193 d fixation in hemiarthroplasty for displaced femoral neck fractures.

194 % in women with baseline osteoporosis at the femoral neck (>2.5 SDs below the normal young adult mean

195 trend for higher annual losses of BMD at the femoral neck; however, within the raloxifene group, lowe

196 significant preservation of bone loss at the femoral neck (HR 1.56, 95% CI 1.21-2.06, P=0.0007).

197 detected signs of impingement on the distal femoral neck (IDFN) in 18 of the 20 patients with SSI (9

198 or treating BMD loss at the lumbar spine and femoral neck in estrogen-deficient women.

199 BMD at all 4 bone sites in women and at the femoral neck in men.

200 mineral density at the lumbar spine and the femoral neck in men.

201 ion reduced bone loss from the total hip and femoral neck in those who consumed <1.5 servings of dair

202 Bone mineral density of the femoral neck increased 6+/-1 percent after 1 year (P=0.0

203 The bone mineral density at the femoral neck increased significantly more in the parathy

204 cement therapy, the rate of bone loss at the femoral neck increased with blood pressure at baseline.

205 The cortex of the femoral neck is a key structural element of the human bo

206 gram to derive geometric measures, including femoral neck length, width, and centroid position.

207 After femoral neck ligature, ADC increased a mean of 27% after

208 s were associated with lower mean BMD at the femoral neck [lowest-to-highest tertiles (95% CI): 0.934

209 d by pQCT, and whole-body, lumbar spine, and femoral neck measurements by DXA.

210 Fluid adjacent to the entire length of the femoral neck, measuring at least 5 mm in width, is compa

211 consortium for lumbar spine (n = 31,800) and femoral neck (n = 32,961) BMD, and from the arcOGEN cons

212 indings, including capsular adhesions at the femoral neck, obliteration of the paralabral sulcus, lab

213 mography the distribution of bone in the mid-femoral neck of 77 proximal femurs from people who died

214 s of cortical bone samples obtained from the femoral neck of hip replacement patients.

215 neral density T score of -2.5 or less at the femoral neck or spine to receive once-daily lasofoxifene

216 No dose-related effect was noted at the femoral neck or the spine.

217 e postmenopausal for 5 years or more, with a femoral neck or total hip bone mineral density T-score b

218 ith base line) and no significant changes in femoral-neck or total-body bone mineral density.

219 D T score of -2.5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture

220 in, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025).

221 umbar spine (P < 0.001), 4.1 +/- 1.0% at the femoral neck (P < 0.001), and 4.6 +/- 0.8% at the femora

222 the L2-L4 lumbar spine vertebra (P < 0.05), femoral neck (P < 0.01), and trochanter (P < 0.01) compa

223 roups with a group x time interaction at the femoral neck (P < 0.04).

224 = .22) but declined at the hip (P = .04) and femoral neck (P = .02).

225 ols, MGUS patients had decreased aBMD at the femoral neck (P = .05) and total femur (P < .05) but no

226 lationship of severe CAL with the BMD of the femoral neck (P = 0.015), as well as a positive associat

227 2 at the hip (p = 0.005), 0.012 g/cm2 at the femoral neck (p = 0.02), 0.015 g/cm2 at the spine (p = 0

228 calcium supplements at the spine (P=0.012), femoral neck (P=0.02), total femur (P=0.003), and intert

229 =0.22), but declined at the hip (p=0.04) and femoral neck (p=0.02).

230 uRBP/uCr and DXA T scores (lumbar [P = .03], femoral neck [P < .001], and total hip [P = .002]).

231 th Crohn's disease (lumbar spine, P = 0.004; femoral neck, P = 0.002).

232 es for preventive consolidation of impending femoral neck pathologic fractures.

233 e more complexly loaded human and chimpanzee femoral necks probably receive more prevalent/predominan

234 IBD (lumbar spine, r = -0.103, p = 0.17 and femoral neck, r = -0.138, p = 0.07).

235 Total body (TB), femoral neck, radius (R), and spine (S) bone mineral den

236 erminate, or spherical), the femoral head-to-femoral neck ratio as an interval measure of femoral hea

237 k of hip OA increased as the femoral head-to-femoral neck ratio decreased (P for trend<0.001) and wit

238 d the prevalence of abnormal femoral head-to-femoral neck ratio in at least 1 hip was 3.70% in contro

239 , the prevalence of abnormal femoral head-to-femoral neck ratio in the unaffected hip was 2 times gre

240 ent angle, acetabular slope, femoral head-to-femoral neck ratio, and the crossover sign) and compared

241 ng of the human femoral neck, the chimpanzee femoral neck reputedly receives relatively simpler loadi

242 In boys only, femoral neck SA-BMC was also significantly and positivel

243 erval measure of femoral head shape, and the femoral neck shaft angle.

244 l grip deformity, wide femoral neck, altered femoral neck-shaft angle, appear to play an important ro

245 Bone mass at total hip, femoral neck, spine (L2-4), and whole body (WB) was dete

246 moderately reduced bone loss measured in the femoral neck, spine, and total body over the three-year

247 ssion, respectively, at the lumbar spine and femoral neck, stratified by male, premenopausal women, a

248 to their lowest baseline T score at spine or femoral neck (stratum I: T score at least -1.0; stratum

249 ctures for those found to have osteoporosis (femoral neck T score < or =-2.5), compared with no inter

250 ad incident fractures, of whom 633 (86%) had femoral neck T scores greater than -2.5.

251 ation of fracture prevalence was best with a femoral neck T-score of -2.0 or less and a value in the

252 alyses showed that type-1 diabetes, baseline femoral neck T-score, interleukin-2 receptor blockade, a

253 odds of fracture, even after adjustment for femoral neck T-score.

254 ronate therapy for postmenopausal women with femoral neck T-scores better than -2.5 and no history of

255 tmenopausal women 55 to 75 years of age with femoral neck T-scores between -1.5 and -2.4.

256 was normal other than mild osteopenia in the femoral neck (T score, -1.3).

257 fracture or low bone mineral density at the femoral neck (T score, lower than -4 or lower than -3 pl

258 sity (BMD) (g/cm(2)), lumbar spine L2-L4 and femoral neck (T-scores) (P = 0.0149, 0.0002 and 0.0139,

259 ratio had a higher rate of bone loss at the femoral neck than did those with a low ratio (P = 0.02)

260 by a T score for bone mineral density at the femoral neck that was more than 4 SD below the mean peak

261 Compared to complex loading of the human femoral neck, the chimpanzee femoral neck reputedly rece

262 walking does not sufficiently load the upper femoral neck, the fragile zones in healthy bones may nee

263 At the femoral neck, the rate of change was -1.6% (95% confiden

264 s were measured in five regions of interest: femoral neck, the Ward triangle, trochanter, intertrocha

265 and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral

266 had significantly lower areal density at the femoral neck; total, cortical, and trabecular volumetric

267 In the human femoral neck, trabecular eccentricity results in a thick

268 the anterior-posterior spine, lateral spine, femoral neck, trochanter, and total body were 4.9% (0.6%

269 %) (P=.002) and prevented bone loss from the femoral neck, trochanter, and total body, despite severe

270 of the anterior-posterior and lateral spine, femoral neck, trochanter, radial shaft, and total body a

271 Bone mineral density (BMD) of the femoral neck, trochanter, total femur, and lumbar spine

272 Bone mineral density (BMD) at the femoral neck, trochanter, total hip, and lumbar spine (L

273 increase in the modified AHA-DLS, BMD at the femoral neck, trochanter, total hip, and lumbar spine (L

274 MD was measured at the proximal right femur (femoral neck, trochanter, Ward's area) with a dual-photo

275 to bone mineral density (BMD) of the spine, femoral neck, trochanter, Ward's triangle, radius, and t

276 density was measured at the proximal femur (femoral neck, Ward triangle, and trochanter) and lumbar

277 mineral density at the lumbar spine (L2-L4), femoral neck, Ward's triangle, and trochanter, both befo

278 Similar decreases were found at the femoral neck, Ward's triangle, and trochanter.

279 es (for example, bone mineral density at the femoral neck was 0.84 g/cm(2), 0.88 g/cm(2), 0.86 g/cm(2

280 en (for example, bone mineral density at the femoral neck was 0.89 g/cm(2) vs. 0.87 g/cm(2), respecti

281 reasing bone mineral density quintile at the femoral neck was 8.35, 5.74, 5.22, 5.00, and 3.38% in wo

282 ule by at least 5 mm along the length of the femoral neck was almost always seen after injection of 5

283 conferring susceptibility to low BMD of the femoral neck was located on chromosome 1p36.

284 ne mineral density (BMD) of lumbar spine and femoral neck was measured, and tryptase and histamine me

285 patients with osteopenia/osteoporosis of the femoral neck was twice that in patients with normal bone

286 BMD Z scores at the lumbar spine and femoral neck were lower in patients with IBD, and lower

287 od pressure, and bone-mineral density at the femoral neck were measured at baseline and bone densitom

288 -score of less than -4.0 at the total hip or femoral neck were not eligible unless they were unable o

289 rements of the lumbar spine (L(2-4)) and the femoral neck were obtained through 1998-1999 by using du

290 n markers (n = 2929) at the lumbar spine and femoral neck were performed in perimenopausal and early

291 Results Capsular adhesions at the anterior femoral neck were present in 12 of the 34 patients (35%)

292 ents, and capsular adhesions at the anterior femoral neck were present in 35% of patients in both gro

293 Fracture loads at the femoral neck were significantly reduced for cecal ligati

294 t, trabecular tracts in human and chimpanzee femoral necks were non-orthogonal (mean approximately 70

295 total body, lumbar spine, and hip (total and femoral neck) were evaluated by using dual-energy X-ray

296 At age 18, smaller lesser trochanter and femoral neck width (FNW) in females still remained altho

297 n 5,245 women (mean age 72.6 years), a wider femoral neck with a more medial centroid position was as

298 The mean increase in bone mass of the femoral neck with estrogen alone (n = 3) was only 0.9%/y

299 vertebral fracture was related to BMD at the femoral neck, with an odds ratio of 1.6 for a 1 SD reduc

300 ndardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization (WHO) BMD catego